PRECISION MEDICINE – Page 3 – REGENHEALTHSOLUTIONS (RHS)

PIER MARIA FORNASARI
2020-02-18

Nivolumab Extends Survival in Pretreated Advanced Stomach Cancer Patients, Phase 3 Trial Results Show

The immune checkpoint inhibitor nivolumab may be a safe and effective treatment for people with advanced gastric or esophagogastric junction cancer who failed standard chemotherapy regimens, results from a Phase 3 clinical trial suggest. A three-year survival analysis of the trial, called ATTRACTION-2 (NCT02267343), showed that the treatment significantly extended patients’ lives and the time they

No Comments InIMMUNOTHERAPY

PIER MARIA FORNASARI
2020-02-11

Study identifies interaction that promotes cancerous state in cells

When the machinery that guides the transition of stem cells to somatic cells doesn’t shut down properly, cells can become cancerous. Identifying the mechanisms that impede those processes would offer scientists a target for cancer research. Purdue University scientists, led by Humaira Gowher, an associate professor in the Department of Biochemistry, have discovered the epigenetic process that

No Comments InCANCER

PIER MARIA FORNASARI
2020-02-07

CRISPR-Edited Cells for Cancer Therapy Safe in Humans: Trial published on Science

In the first clinical study of its kind in the US, researchers used CRISPR to modify CAR T cells to make them more potent against cancer, but the clinical benefits are unknown. mmune cells altered by CRISPR are safe to use in cancer patients, according to results of a clinical trial reported February 6 in Science.

No Comments InCANCER CRISPR

PIER MARIA FORNASARI
2020-02-06

Viruses and cancer – systematic overview published by researchers of DKFZ

Scientists from the German Cancer Research Center systematically investigated the DNA of more than 2,600 tumour samples from patients with 38 different types of cancer to discover traces of viruses – which they found in 13 percent of the samples studied. The researchers also identified mechanisms that the pathogens use to trigger carcinogenic mutations in

No Comments InCANCER

PIER MARIA FORNASARI
2020-02-04

Blocking pro-fibrosis signaling pathway may improve immunotherapy of metastatic breast cancer

A Massachusetts General Hospital (MGH) research team has found that the overgrowth of connective called fibrosis may block the effectiveness of immunotherapies against metastatic breast cancer. Their report published in PNAS also finds that plerixafor, a drug approved to mobilize blood system stem cells in the treatment of lymphoma and multiple myeloma patients, can reduce fibrosis in

No Comments InCANCER

PIER MARIA FORNASARI
2020-02-03

Designing an emergency stop switch for immunotherapies

CAR T-cell therapy is a highly promising treatment strategy for tumors, but is associated with life-threatening side effects. Researchers at EPFL, UNIL and CHUV have developed a new way to “switch off” the therapy when a cancer patient’s life is in danger, paving the way for safer immunotherapy approaches to target solid tumors. Immunotherapy, unlike

No Comments InIMMUNOTHERAPY

PIER MARIA FORNASARI
2020-02-03

Mesoblast submits Ryoncil’s completed biologics license application to US FDA for the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD).

Mesoblast Limited today announced that it has submitted its completed Biologics License Application (BLA) to the United States Food and Drug Administration (US FDA) for Ryoncil™ (remestemcel-L), its lead allogeneic cell therapy for the treatment of children with steroid-refractory acute graft versus host disease (SRaGVHD). Mesoblast filed the final module of the rolling BLA submission,

No Comments InCANCER

PIER MARIA FORNASARI
2020-01-30

Stem Cells, CRISPR and Gene Sequencing Technology are Basis of New Brain Cancer Model

Using genetically engineered human pluripotent stem cells, University of California San Diego School of Medicine researchers created a new type of cancer model to study in vivo how glioblastoma, the most common and aggressive form of brain cancer, develops and changes over time. “We have developed stem cell models that are CRISPR-engineered to have tumor-associated driver mutations

No Comments InCANCER

PIER MARIA FORNASARI
2020-01-24

A single number helps Stanford data scientists find most dangerous cancer cells

Stanford data scientists have shown that figuring out a single number can help them find the most dangerous cancer cells. Biomedical data scientists at the Stanford University School of Medicine have shown that the number of genes a cell uses to make RNA is a reliable indicator of how developed the cell is, a finding that could

No Comments InCANCER

PIER MARIA FORNASARI
2020-01-23

New Technique Predicts Which Melanoma Patients Are at Risk for Cancer Recurrence and Spread

Primary melanoma patients with lower T-cell fraction are 2.5 times more likely to have cancer metastasize than patients with higher T-cell fraction For most patients, melanoma begins with a small, pigmented spot on their skin that they notice starts to change. Many primary melanomas can be cured by having this lesion removed, but melanoma can

No Comments InCANCER

REGENERATIVE AND PERSONALISED MEDICINE

DIGITAL HEALTHCARE

Category PRECISION MEDICINE

Nivolumab Extends Survival in Pretreated Advanced Stomach Cancer Patients, Phase 3 Trial Results Show

Study identifies interaction that promotes cancerous state in cells

CRISPR-Edited Cells for Cancer Therapy Safe in Humans: Trial published on Science

Viruses and cancer – systematic overview published by researchers of DKFZ

Blocking pro-fibrosis signaling pathway may improve immunotherapy of metastatic breast cancer

Designing an emergency stop switch for immunotherapies

Mesoblast submits Ryoncil’s completed biologics license application to US FDA for the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD).

Stem Cells, CRISPR and Gene Sequencing Technology are Basis of New Brain Cancer Model

A single number helps Stanford data scientists find most dangerous cancer cells

New Technique Predicts Which Melanoma Patients Are at Risk for Cancer Recurrence and Spread